Technical Analysis for XBIO - Xenetic Biosciences, Inc.

Grade Last Price % Change Price Change
F 2.14 4.39% 0.09
XBIO closed down 5.09 percent on Monday, April 12, 2021, on 58 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical XBIO trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 4.39%
Wide Bands Range Expansion 4.39%
Narrow Range Bar Range Contraction -0.93%
NR7 Range Contraction -0.93%
Wide Bands Range Expansion -0.93%
Wide Bands Range Expansion -1.83%
Wide Bands Range Expansion 2.88%
Wide Bands Range Expansion 0.94%
Narrow Range Bar Range Contraction -0.47%
NR7 Range Contraction -0.47%
Older End-of-Day Signals for XBIO ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout about 1 hour ago
Rose Above Previous Day's High about 1 hour ago
Rose Above 10 DMA about 1 hour ago
Up 5% about 1 hour ago
Up 3% about 1 hour ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Xenetic Biosciences, Inc. Description

Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research and development of certain pharmaceutical products for use in humans that includes the use of the Company's platform technologies that enables the creation of drug therapies primarily for orphan indications. The Company's technologies include PolyXen, Virexxa, OncoHist and ImuXen. The Company is focused primarily on developing its lead product candidates, including ErepoXen, Virexxa and OncoHist, and PolyXen technology. The Company's lead product candidate ErepoXen, a polysialylated form of erythropoietin (EPO) for the treatment of anemia in pre-dialysis patients with chronic kidney disease, and Food and Drug Administration (FDA) orphan designated oncology therapeutics Virexxa and OncoHist for the treatment of progesterone receptor negative endometrial cancer and refractory Acute Myeloid Leukemia, respectively. It is also developing PSA-FVIII.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Pharmaceutical Industry Pharmaceutical Products Pharmacy Acute Myeloid Leukemia Dialysis FDA Kidney Disease Chronic Kidney Disease Anemia Drug Therapies Endometrial Cancer Platform Technologies Growth Factors Erythropoietin Product Candidates Refractory Acute Myeloid Leukemia

Is XBIO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 5.85
52 Week Low 0.76
Average Volume 367,490
200-Day Moving Average 1.63
50-Day Moving Average 2.59
20-Day Moving Average 2.31
10-Day Moving Average 2.12
Average True Range 0.20
ADX 18.66
+DI 18.36
-DI 28.32
Chandelier Exit (Long, 3 ATRs ) 2.22
Chandelier Exit (Short, 3 ATRs ) 2.51
Upper Bollinger Band 2.73
Lower Bollinger Band 1.88
Percent B (%b) 0.2
BandWidth 37.13
MACD Line -0.13
MACD Signal Line -0.12
MACD Histogram -0.0053
Fundamentals Value
Market Cap 12.91 Million
Num Shares 6.3 Million
EPS -12.32
Price-to-Earnings (P/E) Ratio -0.17
Price-to-Sales 22.59
Price-to-Book 0.88
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.19
Resistance 3 (R3) 2.19 2.16 2.16
Resistance 2 (R2) 2.16 2.12 2.15 2.15
Resistance 1 (R1) 2.10 2.10 2.09 2.10 2.15
Pivot Point 2.07 2.07 2.06 2.06 2.07
Support 1 (S1) 2.01 2.03 2.00 2.01 1.95
Support 2 (S2) 1.98 2.01 1.97 1.95
Support 3 (S3) 1.92 1.98 1.94
Support 4 (S4) 1.92